Research ArticleSpecial Contribution
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman, Lawrence May, David C. Metz, Corina Millo, Sue O'Dorisio, Diane L. Reidy-Lagunes, Michael C. Soulen and Jonathan R. Strosberg
Journal of Nuclear Medicine January 2018, 59 (1) 66-74; DOI: https://doi.org/10.2967/jnumed.117.202275
Thomas A. Hope
1Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia
2American College of Radiology, Reston, Virginia
Emily K. Bergsland
3American Society of Clinical Oncology, Alexandria, Virginia
4North American Neuroendocrine Tumor Society, Albany, New York
Murat Fani Bozkurt
5European Association of Nuclear Medicine, Vienna, Austria
Michael Graham
1Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia
Anthony P. Heaney
6Endocrine Society, Washington, DC
Ken Herrmann
5European Association of Nuclear Medicine, Vienna, Austria
James R. Howe
4North American Neuroendocrine Tumor Society, Albany, New York
7Society of Surgical Oncology, Rosemont, Illinois
Matthew H. Kulke
3American Society of Clinical Oncology, Alexandria, Virginia
4North American Neuroendocrine Tumor Society, Albany, New York
8National Comprehensive Cancer Network, Fort Washington, Pennsylvania
Pamela L. Kunz
3American Society of Clinical Oncology, Alexandria, Virginia
4North American Neuroendocrine Tumor Society, Albany, New York
8National Comprehensive Cancer Network, Fort Washington, Pennsylvania
Josh Mailman
9NorCal CarciNET, Ripon, California
Lawrence May
10American College of Physicians, Washington, DC
David C. Metz
4North American Neuroendocrine Tumor Society, Albany, New York
11American Gastroenterological Association, Bethesda, Maryland; and
Corina Millo
1Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia
Sue O'Dorisio
1Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia
3American Society of Clinical Oncology, Alexandria, Virginia
4North American Neuroendocrine Tumor Society, Albany, New York
Diane L. Reidy-Lagunes
3American Society of Clinical Oncology, Alexandria, Virginia
4North American Neuroendocrine Tumor Society, Albany, New York
Michael C. Soulen
4North American Neuroendocrine Tumor Society, Albany, New York
12Society of Interventional Oncology, Washington, DC
Jonathan R. Strosberg
3American Society of Clinical Oncology, Alexandria, Virginia
4North American Neuroendocrine Tumor Society, Albany, New York
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 1
January 1, 2018
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman, Lawrence May, David C. Metz, Corina Millo, Sue O'Dorisio, Diane L. Reidy-Lagunes, Michael C. Soulen, Jonathan R. Strosberg
Journal of Nuclear Medicine Jan 2018, 59 (1) 66-74; DOI: 10.2967/jnumed.117.202275
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman, Lawrence May, David C. Metz, Corina Millo, Sue O'Dorisio, Diane L. Reidy-Lagunes, Michael C. Soulen, Jonathan R. Strosberg
Journal of Nuclear Medicine Jan 2018, 59 (1) 66-74; DOI: 10.2967/jnumed.117.202275
Jump to section
- Article
- EXECUTIVE SUMMARY
- INTRODUCTION
- METHODOLOGY
- CLINICAL SCENARIOS AND AUC SCORES
- BENEFITS AND HARMS OF IMPLEMENTING THE AUC GUIDANCE
- QUALIFYING STATEMENTS
- IMPLEMENTATION OF THIS AUC GUIDANCE
- APPENDIX A: WORKGROUP MEMBERS AND LITERATURE REVIEWERS
- APPENDIX B: DEFINITION OF TERMS AND ACRONYMS
- APPENDIX C: DISCLOSURES AND CONFLICTS OF INTEREST
- Footnotes
- REFERENCES
- Figures & Data
- Supplemental
- Info & Metrics
Related Articles
Cited By...
- New developments in the imaging of lung cancer
- Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
- 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
- Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors
- 18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
- SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
- Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
- High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT
- Primary versus secondary nature of mesenteric neuroendocrine tumours
- Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET
- Importance of PET with 68Ga-Labeled Somatostatin Analogs (perspective on "68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT" J Nucl Med. 2007;48:508-518)
- 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms
- NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
- SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework